Headache

Neurotherapeutics

Volumn 7, Issue 2, 2010, Pages 149-152

  Goadsby, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; ALNIDITAN; CALCITONIN GENE RELATED PEPTIDE; COL 144; DICLOFENAC; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; LY 344869; N(G) METHYLARGININE; NARATRIPTAN; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OLCEGEPANT; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN AGONIST; SUMATRIPTAN; TELCAGEPANT; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANALGESIA; BRAIN DEPTH STIMULATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; HEADACHE; HUMAN; IONTOPHORESIS; MIGRAINE; NAUSEA AND VOMITING; NERVE BLOCK; NERVE STIMULATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SUPPOSITORY; TENSION HEADACHE; TRANSCRANIAL MAGNETIC STIMULATION;

HEADACHE; HUMANS; NEUROPEPTIDES; NITRIC OXIDE SYNTHASE; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS;

EID: 77953295595     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.03.007     Document Type: Editorial

References (53)

1. Menken M., Munsat T.L., and Toole J.F. The global burden of disease study: implications for neurology. Arch Neurol 57 (2000) 418-420
2. Lipton R.B., Diamond S., Reed M., Diamond M.L., and Stewart W.F. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41 (2001) 638-645
3. Stewart W.F., Ricci J.A., Chee E., Morganstein D., and Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. J Am Med Assoc 290 (2003) 2443-2454
4. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine-current understanding and treatment. New Engl J Med 346 (2002) 257-270
5. Goadsby P.J. The pharmacology of headache. Prog Neurobiol 62 (2000) 509-525
6. Ferrari M.D., Roon K.I., Lipton R.B., and Goadsby P.J. Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358 (2001) 1668-1675
7. Dodick D., Lipton R.B., Martin V., et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 44 (2004) 414-425
8. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (2nd edit). Cephalalgia 24 (2004) 1-160
9. Olesen J., Tfelt-Hansen P., Ramadan N., Goadsby P.J., and Welch K.M.A. The Headaches (2005), Lippincott, Williams & Wilkins, Philadelphia
10. Bertin L., Brion N., Farkkila M., Gobel H., and Wessely P. A dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Int J Clin Pract 53 (1999) 593-598
11. Dahlof C. Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: a review of data from clinical trials. Cephalalgia 21 suppl 1 (2001) 9-12
12. Pierce M., Marbury T., O'Neill C., et al. Zelrix: a novel transdermal formulation of sumatriptan. Headache 49 (2009) 817-825
13. Brandes J.L., Cady R.K., Freitag F.G., et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 49 (2009) 1435-1444
14. Silberstein S.D., Kori S.H., Tepper S.J., et al. Efficacy and tolerability of MAP0004, a novel orally inhaled therapy, in treating acute migraine. Cephalalgia 29 (2009) 12
15. Goadsby P.J. Emerging therapies for migraine. Nature Clin Pract Neurol 3 (2007) 610-619
16. Humphrey P.P.A., Feniuk W., Perren M.J., et al. Serotonin and migraine. Ann NY Acad Sci 600 (1990) 587-598
17. Leysen J.E., Gommeren W., Heylen L., et al. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1Da, human 5-hydroxytryptamine1Db, and calf 5-hydroxytryptamine1D receptors investigated with [3H]-5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 50 (1996) 1567-1580
18. Diener H.C., Tfelt-Hansen P., de Beukelaar F., et al. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia 21 (2001) 672-679
19. Goadsby P.J., and Classey J.D. Evidence for 5-HT1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122 (2003) 491-498
20. Goldstein D.J., Roon K.I., Offen W.W., et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358 (2001) 1230-1234
21. Lassen L.H., Ashina M., Christiansen I., Ulrich V., and Olesen J. Nitric oxide synthesis inhibition in migraine. Lancet 349 (1997) 401-402
22. Ashina M., Lassen L.H., Bendtsen L., Jensen R., and Olesen J. Effect of inhibition of nitric oxide synthase on chronic tension-type headache. Lancet 353 (1999) 287-289
23. Iversen H. Human migraine models. Cephalalgia 21 (2001) 781-785
24. Hoye K., Laurijssens B.E., Harnisch L.O., et al. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine. Cephalalgia 29 (2009) 132
25. Palmer J.E., Guillard F.L., Laurijssens B.E., et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 29 (2009) 124
26. Medve R.A., and Andrews J.S. Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura. Cephalalgia 29 (2009) 126
27. Goadsby P.J., Edvinsson L., and Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28 (1990) 183-187
28. Goadsby P.J., and Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33 (1993) 48-56
29. Doods H., Hallermayer G., Wu D., et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Brit J Pharmacol 129 (2000) 420-423
30. Salvatore C.A., Mallee J.J., Bell I.M., et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 45 (2006) 1881-1887
31. Williams T.M., Stump C.A., Nguyen D.N., et al. Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg Med Chem Lett 16 (2006) 2595-2598
32. Olesen J., Diener H.C., Husstedt I.W., et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350 (2004) 1104-1110
33. Ho T.W., Ferrari M.D., Dodick D.W., et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372 (2008) 2115-2123
34. Zagami A.S., Edvinsson L., Hoskin K.L., and Goadsby P.J. Stimulation of the superior sagittal sinus causes extracranial release of PACAP. Cephalalgia 15 suppl 14 (1995) 109
35. Henrik S., Steffen B., Wienecke T., et al. PACAP38 induces migraine-like attacks and vasodilatation: a causative role in migraine pathogenesis?. Brain 132 (2009) 16-25
36. Rahmann A., Wienecke T., Hansen J.M., et al. Vasoactive intestinal peptide causes marked cephalic vasodilatation but does not induce migraine. Cephalalgia 28 (2007) 226-236
37. Goadsby P.J., Schoenen J., Ferrari M.D., Silberstein S.D., and Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 26 (2006) 1168-1170
38. Goadsby P.J., and Hargreaves R. Refractory migraine and chronic migraine: pathophysiological mechanisms. Headache 48 (2008) 799-804
39. Schulman E.A., Lake III A.E., Goadsby P.J., et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American Headache Society. Headache 48 (2008) 778-782
40. Schulman E.A., Lake III A.E., Goadsby P.J., et al. Defining refractory migraine: results of the RHSIS survey of American Headache Society members. Headache 49 (2009) 509-518
41. Saper J., Goadsby P.J., Silberstein S., and Dodick D.W. Occipital nerve stimulation (ONS) for treatment of intractable chronic migraine (ICM): 3-month results from the ONSTIM feasibility study. Neurology 72 (2009) A252
42. Lipton R.B., Goadsby P.J., Cady R.K., et al. PRISM study: occiptal nerve stimulation for treatment-refractory migraine. Cephalalgia 29 (2009) 30
43. Matharu M.S., Bartsch T., Ward N., et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127 (2004) 220-230
44. Bartsch T., and Goadsby P.J. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 125 (2002) 1496-1509
45. Bartsch T., and Goadsby P.J. Increased responses in trigeminocervical nociceptive neurones to cervical input after stimulation of the dura mater. Brain 126 (2003) 1801-1813
46. Burns B., Watkins L., and Goadsby P.J. Successful treatment of medically intractable cluster headache using occipital nerve stimulation (ONS). Lancet 369 (2007) 1099-1106
47. Burns B., Watkins L., and Goadsby P.J. Treatment of hemicrania continua by occipital nerve stimulation using the novel bion device: long term follow up of six patients. Lancet Neurol 7 (2008) 1001-1012
48. May A., Bahra A., Buchel C., Frackowiak R.S., and Goadsby P.J. Hypothalamic activation in cluster headache attacks. Lancet 352 (1998) 275-278
49. May A., Ashburner J., Buchel C., et al. Correlation between structural and functional changes in brain in an idiopathic headache syndrome. Nature Med 5 (1999) 836-838
50. Leone M., Franzini A., and Bussone G. Stereotatic stimulation of the posterior hypothalamic gray matter in a patient with intractable cluster headache. New Engl J Med 345 (2001) 1428-1429
51. Lipton R.B., Dodick D.W., Silberstein S.D., et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9 (2010) 373-380
52. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 117 (1994) 199-210
53. Holland P.R., Schembri C.T., Fredrick J.P., and Goadsby P.J. Transcranial magentic stimulation for the treatment of migraine aura. Neurology 72 (2009) A250